ClinicalTrials.Veeva

Menu

Evaluation of The Comfort of Orthokeratology Lenses Fit Using A New Software

CooperVision logo

CooperVision

Status

Enrolling

Conditions

Myopia

Treatments

Device: control contact lens

Study type

Interventional

Funder types

Industry

Identifiers

NCT05389072
SEC-P042021

Details and patient eligibility

About

As new orthokeratology fitting software emerges onto the market, it is of interest to assess their usefulness in guiding eye practitioners with lens fit. The goal of this study is to evaluate the comfort of Paragon orthokeratology lenses when they are fit using the new Procornea software.

Enrollment

57 estimated patients

Sex

All

Ages

6 to 35 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Are 6- 35 years of age
  2. Have had a self-reported visual exam in the last two years
  3. Have a contact lens refraction that fits within the available parameters of the study lenses
  4. Are able to read (or be read to), understand and sign the assent document if under 18 years old or are able to read, understand and sign the consent document if aged 18 or older (Children 6-years of age will not be asked to sign the assent form as per STERLING IRB.);
  5. Are under 18 years old and are accompanied by a parent or legal guardian who is able to read, understand and sign the parental information and permission document;
  6. Are willing to comply with the wear schedule (8 hour per night for every night, while sleeping)
  7. Are willing to comply with the visit schedule
  8. Have a refractive spherical component of their prescription between -0.50 and up to -6.00 diopters (inclusive) AND a refractive cylinder of no more than -1.75 diopters
  9. Have a refractive spherical component ≥ cylinder component
  10. Have a minimum visual acuity of +0.20 logMAR with each eye, when refracted at the Screening visit
  11. Have clear corneas and no active ocular disease
  12. Have no medication, medical condition, or ocular conditions that contraindicate contact wear OR are expected to affect lens comfort or vision across the 1-month study duration, in the opinion of the investigator
  13. Can be shown to have stable keratometry for at least the previous 1 month, if they have previously worn orthokeratology lenses.

Exclusion criteria

  1. Present at screening visit with the presence of ocular or systemic disease or reports the use medications which might interfere with orthokeratology contact lens wear, such as keratoconus, diabetes mellitus, steroid eye drops

  2. Have a post-treatment predicted flat K value ≤38.00D (e.g. Patient baseline flat keratometry value = 40.00, patient has 2.00D of myopic refractive error. 40.00-2.00= 38.00D)

  3. Have a known sensitivity to the diagnostic sodium fluorescein to be used in the study

  4. Are pregnant, planning a pregnancy or lactating

  5. Have amblyopia

  6. Have presbyopia or has dependence on spectacles for near work over the contact lenses

  7. Present at screening visit with the presence of clinically significant (grade >3; Efron scale) anterior segment abnormalities.

  8. Present at screening visit with slit lamp findings that would contraindicate orthokeratology contact lens wear such as:

    1. Pathological dry eye or associated findings
    2. Pterygium, pinguecula, or corneal scars within the visual axis
    3. Neovascularization > 0.75 mm from of the limbus
    4. Giant papillary conjunctivitis (GPC) worse than grade 1
    5. Anterior uveitis or iritis (past or present)
    6. Seborrheic eczema, Seborrheic conjunctivitis
    7. History of corneal ulcers or fungal infections
    8. Poor personal hygiene
    9. Aphakia

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

57 participants in 1 patient group

Control Lens
Experimental group
Treatment:
Device: control contact lens

Trial contacts and locations

4

Loading...

Central trial contact

Jose Vega, OD; Kelly Voltz, OD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems